Characterization of the Pharmacokinetics and Physiological Effects of Tapentadol in Horses
Journal of Veterinary Pharmacology and Therapeutics · 2026
DOI: 10.1111/jvp.70089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2026. Verfasst von Annabella D Lynch und 4 weiteren Autor:innen. Beteiligte Einrichtung: K. L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, Davis, Cal…. Hauptthemen laut MEDLINE: Phenols, Analgesics, Opioid. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, Kenneth L Maddy Equine Analytial Chemistry Laboratory Program, Center for Equine Health, School of Veterinary Medicine, University of California, Davis.
Abstract (Originalsprache)
Tapentadol is a dual mechanism analgesic utilizing both μ‐opioid receptor (MOR) agonism and norepinephrine reuptake inhibition (NRI). This study evaluated the pharmacokinetics and pharmacodynamics of tapentadol as a potential analgesic with the goal of treating pain in horses. Pharmacokinetics of both tapentadol and tapentadol‐O‐glucuronide were elucidated. Six horses received three separate escalating single oral doses (1, 3, and 5 mg/kg) and a single intravenous (0.32 mg/kg) dose of tapentadol in a four‐period sequential design. Concentrations of tapentadol and tapentadol‐O‐glucuronide were determined using liquid chromatography–tandem mass spectrometry. The maximum concentrations (mean ± SD) in plasma following administration of 1, 3, 5 mg/kg oral tapentadol were 7.98 ± 6.95, 39.8 ± 53.8, and 210.6 ± 234.4 ng/mL at 0.75, 0.63, and 0.38 h, respectively. Maximum plasma concentration (mean ± SD) after a single 0.32 mg/kg IV dose was 339.2 ± 83.5 ng/mL. The maximum concentrations of tapentadol‐O‐glucuronide following single 1, 3, and 5 mg/kg oral doses and a single 0.32 mg/kg IV dose of tapentadol were 532.6 ± 171.4, 1169.4 ± 345.4, 1559.5 ± 574.6, and 226.4 ± 51.5 ng/mL at times 6.0, 6.0, 7.0, and 0.5 h. Tapentadol was well‐tolerated at all doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- K. L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, Davis, California, USA.
- Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, California, USA.
- Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado, USA.
- Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, Fort Collins, Colorado, USA.
ORCID-Profile: Heather K Knych
Förderung
- NIGMS NIH HHS
- Kenneth L Maddy Equine Analytial Chemistry Laboratory Program
- Center for Equine Health, School of Veterinary Medicine, University of California, Davis
- NIH Pharmacology Training Grant
- UC Davis Center for Equine Health
Zitieren
APA
Lynch, A. D., Mama, K. R., McKemie, D. S., Kass, P. H., & Knych, H. K. (2026). Characterization of the Pharmacokinetics and Physiological Effects of Tapentadol in Horses. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.70089
Vancouver
Lynch AD, Mama KR, McKemie DS, Kass PH, Knych HK. Characterization of the Pharmacokinetics and Physiological Effects of Tapentadol in Horses. Journal of Veterinary Pharmacology and Therapeutics. 2026. doi:10.1111/jvp.70089
BibTeX
@article{Lynch2026,
author = {Lynch, Annabella D and Mama, Khursheed R and McKemie, Dan S and Kass, Phillip H and Knych, Heather K},
title = {Characterization of the Pharmacokinetics and Physiological Effects of Tapentadol in Horses},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2026},
doi = {10.1111/jvp.70089}
}
EUVIMED